Maternal Experiences With Human Papillomavirus and Vaccination Rates in Children—The Sound of Salience
Menée à partir de données 2014-2018 portant sur 757 428 enfants d'au moins 11 ans, cette étude analyse les différences concernant la vaccination contre le papillomavirus humain chez les enfants ayant des antécédents maternels de cancer du col de l'utérus ou de biopsie cervicale
Human papillomavirus (HPV) vaccination in the US continues to lag well behind the national goal of 80% series completion. There have been many efforts to identify factors associated with vaccine acceptance, with some of the most consistent and significant factors being the quality of the clinician’s recommendation and parental health beliefs. In JAMA Network Open, Worsham et al used a large insurance claims database to examine a third factor—salience. They wanted to discover whether salience of maternal HPV disease outcomes (ie, history of cervical cancer or cervical biopsy) led to higher HPV vaccination rates among children when compared with children of mothers with no such history. In the multivariable analyses of time to first dose and time to second dose, there was no significant difference between mothers who had a history of cervical cancer and those who did not, and this lack of significance held for both boys and girls. Interestingly, there were statistically significant differences for cervical biopsy; in both sets of analyses, boys and girls whose mothers had a history of cervical biopsy were more likely to receive the first and second doses of HPV vaccine than children whose mothers did not. The authors note that although statistically significant, this effect size was relatively small, suggesting limited clinical significance.
JAMA Network Open , éditorial en libre accès, 2020